DaveFoster
Member
T3 treats major depressive disorder (MDD), where hypothyroidism appears alongside various neuroses including generalized anxiety disorder (GAD), phobias including social anxiety disorder (SAD), personality disorders (which often feature elevated cortisol and low DHEA), and lastly obsessive-compulsive disorder (OCD).
This study shows that T3 can also treat bipolar disorder (even treatment-resistant bipolar disorder), both by itself or in conjunction with a drug such as lithium (with actions similar to sodium) or other anticonvulsants (such as lamotrigine).
"Patients had been unsuccessfully treated with an average of 14 other medications before starting T3. At an average dose of 90.4 mcg (range 13 mcg-188 mcg) the medication was well tolerated. None of the patients experienced a switch into hypomania, and only 16 discontinued due to side effects. Improvement was experienced by 84%, and 33% experienced full remission."
"A high percentage of bipolar II and bipolar NOS patients with treatment resistant depression improved on T3. Despite the use of higher than usual doses in many of the patients, the medication was well tolerated. Augmentation with supraphysiologic doses of T3 should be considered in cases of treatment resistant bipolar depression."
SOURCE: The use of triiodothyronine as an augmentation agent in treatment-resistant bipolar II and bipolar disorder NOS. - PubMed - NCBI
Original posted on the Foster Your Health blog: T3 Treats Bipolar Disorder
This study shows that T3 can also treat bipolar disorder (even treatment-resistant bipolar disorder), both by itself or in conjunction with a drug such as lithium (with actions similar to sodium) or other anticonvulsants (such as lamotrigine).
"Patients had been unsuccessfully treated with an average of 14 other medications before starting T3. At an average dose of 90.4 mcg (range 13 mcg-188 mcg) the medication was well tolerated. None of the patients experienced a switch into hypomania, and only 16 discontinued due to side effects. Improvement was experienced by 84%, and 33% experienced full remission."
"A high percentage of bipolar II and bipolar NOS patients with treatment resistant depression improved on T3. Despite the use of higher than usual doses in many of the patients, the medication was well tolerated. Augmentation with supraphysiologic doses of T3 should be considered in cases of treatment resistant bipolar depression."
SOURCE: The use of triiodothyronine as an augmentation agent in treatment-resistant bipolar II and bipolar disorder NOS. - PubMed - NCBI
Original posted on the Foster Your Health blog: T3 Treats Bipolar Disorder